Note: The below is an edited version of an article originally published on Globe Newswire. The original release can be read in its entirety here.
uniQure N.V. yesterday announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B. The updated data show that all five of the patients in the low-dose cohort have sustained improvements in their disease phenotype and continue to maintain durable levels of Factor IX gene activity for up to 39 weeks post treatment. At up to 9 months of follow up, AMT-060 continues to be well-tolerated.